Prof. Dr. Andreani Odysseos

 

Harvard Club of Cyprus co-founder, Research Director of EPOS-Iasis, R&D and Head of the Translational Nanomedicine and Nanobiotechnology Lab through a special academic appointment at the University of Cyprus, leads revolutionary Translational Research in Nano-biotechnology, Externally Controllable Molecular Communications for Cancer sensing and therapy, including wearable and implantable devices, supporting Digital Twin and Internet of Biothings evolution and implementation. She is a graduate of University of Athens Medical School and conducted her doctoral research and clinical post-doctoral studies at Dana – Farber Cancer Institute, Discipline of Tumour Immunology and Fred-Hutchinson Cancer Research Center. She was First Price recipient of CyEnterpreneurship Competition through which she established EPOS, leading a vibrant interdisciplinary team for Translational Nanomedicine, Cell Therapies and Hybrid (cell+electronics) Theranostic Systems. She has attracted national and EC funding amassing € ~7.5M, including IAPP and ITN MSCAs, IMI, R& I Actions and three most prestigious EIC Pathfinder grants on management of brain pathologies with Externally Controllable Molecular Communications. Her innovative findings in Optical Biosensing Interfaces and Targeted Nano-therapeutics have been secured in 8 patents (5US, 2EPO, 1WIPO) and published in peer-reviewed papers, book chapters and monographs. Scholarly Activities include Foundation and first Vice-Chairmanship of the European Federation of Biotechnology-Section of Medicines Development and Cluster Management Group, EUREKA Cluster on New Safe Medicines Faster. She has been an evaluator in EC FP7, H2020, ERC, EUROSTARS, EUREKA, Independent Expert Panel (Nominated by the Cyprus Research and Innovation Foundation), Norway Programs, Ministry of Science, Poland, STRATEGMED, EuroNanoMed- Invited Expert, 2017-2020. She is a member of the EITHealth, a ‘knowledge and innovation community’ a ‘knowledge and innovation community’ (KIC) of the European Institute of Innovation and Technology, strengthening innovation transfer potential. Currently she serves on the HORIZON Europe EIC Transition Jury. Her work integrating Biomedical Sciences, Biomedical Engineering and Artificial Intelligence, contributing to clinically applicable emerging technologies for the management of Cancer and Neurodegenerative Disorders has been acknowledged by the International Academy for Medical Education (IAMED) with an honorary membership.